Humacyte’s (HUMA) Buy Rating Reiterated at D. Boral Capital

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $25.00 price target on the stock.

Other equities analysts also recently issued reports about the stock. Benchmark reaffirmed a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Humacyte in a report on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $13.71.

Humacyte Stock Performance

Shares of NASDAQ:HUMA opened at $2.01 on Wednesday. The business has a fifty day moving average of $3.66 and a 200-day moving average of $4.53. Humacyte has a twelve month low of $1.96 and a twelve month high of $9.97. The firm has a market cap of $252.98 million, a PE ratio of -1.50 and a beta of 1.36.

Hedge Funds Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently bought and sold shares of HUMA. Woodline Partners LP lifted its stake in shares of Humacyte by 235.7% in the 4th quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock valued at $14,386,000 after purchasing an additional 2,000,268 shares during the period. State Street Corp boosted its holdings in Humacyte by 66.1% during the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after buying an additional 1,895,529 shares during the last quarter. CenterBook Partners LP bought a new stake in shares of Humacyte in the 4th quarter valued at about $6,463,000. Brevan Howard Capital Management LP boosted its stake in Humacyte by 2,795.1% during the 4th quarter. Brevan Howard Capital Management LP now owns 876,340 shares of the company’s stock worth $4,426,000 after acquiring an additional 846,070 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in Humacyte by 10.8% during the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock valued at $28,294,000 after purchasing an additional 543,995 shares during the period. 44.71% of the stock is owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.